An invaluable book containing a series of interdisciplinary
discussions between clinical and basic scientists. Biology
of IGF-1: Its interaction with insulin and health and malignant
states focuses on key issues such as:

• the definition of danger zones

• the development of methods for early recognition of malignant
  states linked to IGF-1 and/or insulin

• possible approaches to preventative intervention

• the relevance in this field of research to the development of
  novel therapeutic approaches to treating certain cancers.

  Autorentext

  The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.

  Zusammenfassung
  An invaluable book containing a series of interdisciplinary discussions between clinical and basic scientists. Biology of IGF-1: Its interaction with insulin and health and malignant states focuses on key issues such as:

• the definition of danger zones
• the development of methods for early recognition of malignant states linked to IGF-1 and/or insulin
• possible approaches to preventative intervention

• the relevance in this field of research to the development of novel therapeutic approaches to treating certain cancers.

  Inhalt

  Chair's Introduction (Leroith). Circulating IGF-I and its role in cancer: lessons from the IGF-1 gene-deletion (LID) mouse (Yakar et al).

  Physiology of the IGF system (Holly).

  Molecular basis of insulin action (Zick).

  IGF-1 and insulin as growth hormones (Laron).

  Insulin-like growth factors and neoplasia (Pollak).

  Loss of IGF2 imprinting: mechanisms and consequences (Ohlsson).

  Insulin and IGF-1 receptor trafficking and sginalling (Foti et al).

  The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb (Nobukini and Thomas).

  Structural biology of insulin and IGF-1 receptors (De Meyts et al).

  Genetic blockade of the insulin-like growth factor-I receptor for human malignancy (Adachi et al).

  IGF-1 and prostate cancer (Roberts Jr.).

  IGF-1 and breast cancer (Lonning and Helle).

  IGFBPs and cancer (Fang et al).

  The IGF receptor as anti-cancer treatment target (Macaulay).

  Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence (Kaaks).

  Final discussion.

  Index of contributors.

  Subject index.